Farmas USA

¿KBIO también es chicharro ?? Tiene un 69% de Institucionales...

Fíate de esto, que esos datos de estudios no son buenos y estos son del último informe.

Paran el estudio cuya reanudación ha autorizado la FDA (ATHENA) para analizar los datos. También paran por ahora otro estudio de células adiposas regenerativas que estaban iniciando y otro ortopédico (RECOVER).

during the delay the Company has made substantial progress on it next generation Celution® system, the Company has determined the most prudent course of action is to stop enrollment at 31 patients and analyze unblinded six month data. The 31st patient will reach the planned 6 month time-point this month. An analysis of the complete and verified 6 month data should be available early in 2015 for review and planning next steps.

adipose-derived regenerative cells (ADRCs) in the therapy of patients with end-stage heart failure already on a left ventricular assist device or LVAD in a trial called CELVAD. Recently, the NHLBI informed Cytori that initiation of a cell therapy trial on patients with LVADs will be delayed citing concerns around the feasibility related to treatment of LVAD patients, evolving nature of LVADs, endpoint selection, and the cost and complexity of the study. We will provide updates on the outlook for this trial when we are notified.

Inician uno ortopédico

eceived approval by the FDA to begin a US IDE pilot (phase II a/b) clinical trial of Cytori Cell Therapy in patients with osteoarthritis affecting the knees to be called ACT-OA. A total of 90 patients will be enrolled in this randomized, double-blind, placebo controlled clinical trial and followed for one year. The study, which is anticipated to begin enrollment in 2015, will examine the safety of Cytori Cell Therapy and several efficacy endpoints including symptom relief, function and activity level. Data should be available in 2016.

Participan en otro de escleroderma

Cytori has agreed to support a follow up confirmatory trial in France.

BARDA executed a significant contract extension option for ongoing research and development activities required to enable a pilot clinical trial of Cytori Cell Therapy in thermal burn treatment;

Resumen: Cytori intends to: finalize ATHENA and analyze the data, start the ACT-OA trial, wind down the RECOVER trial, support the initiation of its scleroderma and urinary incontinence trials in Europe and Japan respectively, file for CFDA class I approval, complete the next phase of the Celution® development program, and work with BARDA and FDA to plan our forthcoming thermal burn trial, among other activities. Financially, we intend to continue to improve our financial position through combination of activities including: additional expense reductions, profitable revenue growth, additional capital raise, partnerships, debt restructure or further debt term modification.

http://finance.yahoo.com/news/cytori-reports-third-quarter-2014-210500145.html

Sobre las quemaduras thermal burn
http://ir.cytori.com/investor-relations/News/news-details/2014/BARDA-Executes-Contract-Option-with-Cytori-for-Continued-Development-of-Thermal-Burn-Injury-Counter-Measure/default.aspx
FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
http://www.streetinsider.com/Corporate+News/Cytori+Therapeutics+%28CYTX%29+Reports+FDA+Granted+Conditional+Approval+for+U.S.+Pivotal+Clinical+Trial+in+Scleroderma/10084748.html?si_client=intbro
http://seekingalpha.com/article/2711865-cytori-why-this-undervalued-cell-therapy-biotech-is-a-buy

KBIO

Capitalización de 18 millones. Eso lo dice todo...

Chicharrazo donde los haya.

El % de institucionales ahi no influye. 

Es la capitalizacion, KBIO : 17 millones $ incluyendo la subida del +10% que lleva hoy.

Pat12, las categorias van como siguen:

Nano Cap : Hasta 50 mill $  CHICHARRAZO SUPREMO
Micro Cap : 50 a 300 mill $ CHICHARRO
Small Cap : 300 mill $ a 2 Billones $ - BICHAS DE AMPLIO ESPECTRO
Mid Cap : 2 a 10 Billones $ 
Large Cap : 10 a 100 Billones $ 
Mega Cap : Desde 100 Billones $

Todos las páginas que visito la ponen bien ....fijate esta por ejemplo:

http://www.barchart.com/opinions/stocks/CYTX

Pero claro estas que suben tan deprisa tal como suben bajan.

CYTX

Cytori Therapeutics (CYTX) Highly Overbought Following Recent Run

Empieza la fiesta

http://www.streetinsider.com/Trader+Talk/Cytori+Therapeutics+%28CYTX%29+Highly+Overbought+Following+Recent+Run/10322346.html?si_client=intbro

Gracias Framus estos datos que me has dado me los voy a guardar. esperando que a tener disponible ya el dinero en cuenta de la venta de ARIAD y estoy mirando a ver donde me puedo meter pero parece que tengo imán para los chicharros. Y es que lo barato ....ná, que no se puede ser pobre :-) Buen finde a todos !

Pat12, tu llamas barato a BAJO PRECIO.

Si te digo que hay valores a 20$ que estan mas baratos que otros que puedas comprar a 0,50$???

Todo depende del valor que le des a lo que compras.